drugset / Trial / NCT00244426
S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
RandomizedParallel-groupTriple-blindPrevention
Summary
Evaluate efficacy and safety of Indobufen v. Aspirin in preventing thromboembolic events in patients at high risk of CV events such as patients suffering from nonrheumatic atrial fibrillation.
Timeline
- Start
- 2000-12
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 300 mg | — |
| Subject | Indobufen | Small molecule | 100 mg | — |
| Subject | Indobufen | Small molecule | 200 mg | — |